Literature DB >> 32462403

Updating dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2): molecular basis, functions and role in diseases.

Alejandro Correa-Sáez1,2,3, Rafael Jiménez-Izquierdo1,2,3, Martín Garrido-Rodríguez1,2,3, Rosario Morrugares1,2,3, Eduardo Muñoz1,2,3, Marco A Calzado4,5,6.   

Abstract

Members of the dual-specificity tyrosine-regulated kinase (DYRKs) subfamily possess a distinctive capacity to phosphorylate tyrosine, serine, and threonine residues. Among the DYRK class II members, DYRK2 is considered a unique protein due to its role in disease. According to the post-transcriptional and post-translational modifications, DYRK2 expression greatly differs among human tissues. Regarding its mechanism of action, this kinase performs direct phosphorylation on its substrates or acts as a priming kinase, enabling subsequent substrate phosphorylation by GSK3β. Moreover, DYRK2 acts as a scaffold for the EDVP E3 ligase complex during the G2/M phase of cell cycle. DYRK2 functions such as cell survival, cell development, cell differentiation, proteasome regulation, and microtubules were studied in complete detail in this review. We have also gathered available information from different bioinformatic resources to show DYRK2 interactome, normal and tumoral tissue expression, and recurrent cancer mutations. Then, here we present an innovative approach to clarify DYRK2 functionality and importance. DYRK2 roles in diseases have been studied in detail, highlighting this kinase as a key protein in cancer development. First, DYRK2 regulation of c-Jun, c-Myc, Rpt3, TERT, and katanin p60 reveals the implication of this kinase in cell-cycle-mediated cancer development. Additionally, depletion of this kinase correlated with reduced apoptosis, with consequences on cancer patient response to chemotherapy. Other functions like cancer stem cell formation and epithelial-mesenchymal transition regulation are also controlled by DYRK2. Furthermore, the pharmacological modulation of this protein by different inhibitors (harmine, curcumine, LDN192960, and ID-8) has enabled to clarify DYRK2 functionality.

Entities:  

Keywords:  Apoptosis; Cancer; Cell cycle; DYRK2; Disease; Kinase; Phosphorylation

Year:  2020        PMID: 32462403     DOI: 10.1007/s00018-020-03556-1

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  9 in total

1.  The immune factors driving DNA methylation variation in human blood.

Authors:  Etienne Patin; Lluís Quintana-Murci; Jacob Bergstedt; Sadoune Ait Kaci Azzou; Kristin Tsuo; Anthony Jaquaniello; Alejandra Urrutia; Maxime Rotival; David T S Lin; Julia L MacIsaac; Michael S Kobor; Matthew L Albert; Darragh Duffy
Journal:  Nat Commun       Date:  2022-10-06       Impact factor: 17.694

2.  Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancer.

Authors:  Kai Yuan; Zhaoxing Li; Wenbin Kuang; Xiao Wang; Minghui Ji; Weijiao Chen; Jiayu Ding; Jiaxing Li; Wenjian Min; Chengliang Sun; Xiuquan Ye; Meiling Lu; Liping Wang; Haixia Ge; Yuzhang Jiang; Haiping Hao; Yibei Xiao; Peng Yang
Journal:  Nat Commun       Date:  2022-05-25       Impact factor: 17.694

Review 3.  Regulation of the SIAH2-HIF-1 Axis by Protein Kinases and Its Implication in Cancer Therapy.

Authors:  Dazhong Xu; Cen Li
Journal:  Front Cell Dev Biol       Date:  2021-03-25

Review 4.  Emerging roles of DYRK2 in cancer.

Authors:  Vasudha Tandon; Laureano de la Vega; Sourav Banerjee
Journal:  J Biol Chem       Date:  2021-01-07       Impact factor: 5.157

5.  Two adjacent phosphorylation sites in the C-terminus of the channel's α-subunit have opposing effects on epithelial sodium channel (ENaC) activity.

Authors:  Alexei Diakov; Viatcheslav Nesterov; Anke Dahlmann; Christoph Korbmacher
Journal:  Pflugers Arch       Date:  2022-05-08       Impact factor: 4.458

6.  A pan-cancer analysis of the oncogenic role of dual-specificity tyrosine (Y)-phosphorylation- regulated kinase 2 (DYRK2) in human tumors.

Authors:  Xinyue Qiu; Cheng Shen; Wenjing Zhao; Xunlei Zhang; Dakun Zhao; Xuming Wu; Lei Yang
Journal:  Sci Rep       Date:  2022-09-14       Impact factor: 4.996

Review 7.  Roles of dual specificity tyrosine-phosphorylation-regulated kinase 2 in nervous system development and disease.

Authors:  Gabriel Nicolás Santos-Durán; Antón Barreiro-Iglesias
Journal:  Front Neurosci       Date:  2022-09-08       Impact factor: 5.152

Review 8.  Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.

Authors:  Mattias F Lindberg; Laurent Meijer
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923

9.  A novel CDC25A/DYRK2 regulatory switch modulates cell cycle and survival.

Authors:  Maribel Lara-Chica; Alejandro Correa-Sáez; Rafael Jiménez-Izquierdo; Martín Garrido-Rodríguez; Francisco J Ponce; Rita Moreno; Kimberley Morrison; Chiara Di Vona; Krisztina Arató; Carla Jiménez-Jiménez; Rosario Morrugares; M Lienhard Schmitz; Susana de la Luna; Laureano de la Vega; Marco A Calzado
Journal:  Cell Death Differ       Date:  2021-08-06       Impact factor: 15.828

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.